Philip J. Rosenfeld, M.D., Ph.D., is a world-renown expert on age-related macular degeneration (AMD) and optical coherence tomography (OCT). He has played a pivotal role in the development of anti-VEGF therapies for neovascular and exudative eye diseases. He revolutionized the treatment of these diseases by pioneering the use of intravitreal Avastin (bevacizumab) therapy, which has prevented blind… Read more ›
| University | Degree | Focus | Graduated |
|---|---|---|---|
| Johns Hopkins University School of Medicine | Doctorate | Other | 1988 |
| Johns Hopkins University School of Medicine (Doctoral Program) | Other Degree | Molecular Biology & Genetics | 1988 |
| Institution | Focus | Year |
|---|---|---|
| Residency - Harvard/Massachusetts Eye and Ear Infirmary | Ophthalmology | 1995 |
| Residency - Johns Hopkins Hospital | Obstetrics & Gynecology | 1991 |
| Fellowship - Harvard/Massachusetts Eye and Ear Infirmary | Retinal Degeneration | 1992 |
| Fellowship - UMHC - Bascom Palmer Eye Institute | Vitreoretinal Diseases & Surgery | 1996 |
| Certification | Cert. Body | Year |
|---|---|---|
| Ophthalmology | Ophthalmology | Not Specified |
Ophthalmology
Years In Practice: 30 (started in 1995)
Accepts New Patients: No
Philip J Rosenfeld, MD, PhD has not yet listed the medications that he commonly prescribes.
Philip J Rosenfeld, MD, PhD has not yet specified the insurance plans he accepts.
